Shopping Cart
- Remove All
Your shopping cart is currently empty
PD0325901-O-C2-dioxolane
🥰Excellent
Catalog No. T40217Cas No. 2581116-22-3
The main body of PD0325901-O-C2-dioxolane is PD0325901, which is a typical non-ATP-competitive MEK1/2 (mitogen-activated protein kinase) inhibitor occupying a variant-binding pocket near the ATP-binding site, with anticancer effects of decreasing ERK phosphorylation and inhibiting cell proliferation.
PD0325901-O-C2-dioxolane
🥰Excellent
Catalog No. T40217Cas No. 2581116-22-3
The main body of PD0325901-O-C2-dioxolane is PD0325901, which is a typical non-ATP-competitive MEK1/2 (mitogen-activated protein kinase) inhibitor occupying a variant-binding pocket near the ATP-binding site, with anticancer effects of decreasing ERK phosphorylation and inhibiting cell proliferation.
Product information is being updated, if you want to purchase, please click the bulk custom button.
Bulk & Custom
Questions
View MoreInhibitors Related to "PD0325901-O-C2-dioxolane"
(+)-JQ-1
Cited
JQ1
T21101268524-70-4
(+)-JQ-1 (JQ1) is a specific, reversible BET bromine domain inhibitor that targets BRD4 (1/2) with IC50 values of 77/33 nM. (+)-JQ-1 induces cell autophagy and inhibits cell proliferation.
- $30
Size
QTY
CitedLidocaine hydrochloride Cited
Xyloneural, Lignocaine hydrochloride, Lidothesin, Lidocaine HCL
T114473-78-9
Lidocaine hydrochloride (Lignocaine hydrochloride) is a local anesthetic and cardiac depressant used as an antiarrhythmic agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
- $45
Size
QTY
CitedPD184161
T21635212631-67-9
PD184161 is a novel, orally-active MEK inhibitor. PD184161 inhibited MEK activity (IC50 = 10-100 nM) in a time- and concentration-dependent manner[1].
- $32
Size
QTY
Binimetinib Cited
MEK162, ARRY-438162, ARRY-162
T2508606143-89-9
Binimetinib (ARRY-162) is a MEK1/2 inhibitor (IC50=12 nM) with selective and oral activity. Binimetinib has antitumor activity for the treatment of metastatic melanoma that cannot be resected or has a BRAF V600E or V600K mutation.
- $35
Size
QTY
CitedPelitinib Cited
WAY-EKB 569, EKB-569
T2327257933-82-7
Pelitinib (EKB-569) (EKB-569) is an effective irreversible EGFR inhibitor (IC50: 38.5 nM).
- $43
Size
QTY
CitedTrametinib Cited
JTP-74057, GSK1120212
T2125871700-17-3
Trametinib (GSK1120212) is a MEK inhibitor that inhibits MEK1 and MEK2 (IC50=0.7/0.9 nM) with ATP non-competitive and oral activity. Trametinib activates autophagy and induces apoptosis.
- $31
Size
QTY
CitedLidocaine
Xylocaine, Lignocaine, Alphacaine
T0468137-58-6
Lidocaine (Alphacaine) is an amide local anesthetic with anti-inflammatory properties in vitro and in vivo. It has this functions perhaps due to an attenuation of intracellular adhesion molecule-1 (ICAM-1), pro-inflammatory cytokines, and reduction of neutrophils influx.
- $45
Size
QTY
Honokiol Cited
NSC 293100
T300135354-74-6
Honokiol (NSC-293100) is the active principle of magnolia extract. It inhibits the activation of Akt and enhances the phosphorylation of ERK1/ERK2.
- $50
Size
QTY
CitedIbrutinib Cited
PCI-32765
T1835936563-96-1
Ibrutinib (PCI-32765) is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
- $36
Size
QTY
CitedU0126-EtOH Cited
U0126 Ethanol, U0126
T62231173097-76-1
U0126-EtOH (U0126 Ethanol) is a non-ATP competitive specific inhibitor of MEK1/2 (IC50: 0.07/0.06 μM).
- $30
Size
QTY
CitedDasatinib carbaldehyde
PROTAC ABL binding moiety 4, BMS-354825 carbaldehyde
T185952112837-79-1
Dasatinib carbaldehyde (PROTAC ABL binding moiety 4) is based on Dasatinib which is an ABL inhibitor, binds to the IAP ligand via a linker, and forms SNIPER [1].
- $30
Size
QTY
Select Batch
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | The main body of PD0325901-O-C2-dioxolane is PD0325901, which is a typical non-ATP-competitive MEK1/2 (mitogen-activated protein kinase) inhibitor occupying a variant-binding pocket near the ATP-binding site, with anticancer effects of decreasing ERK phosphorylation and inhibiting cell proliferation. |
| In vitro | PD0325901 is a potent non-ATP competitive MEK inhibitor that effectively suppresses ERK signaling and tumor cell proliferation [1]. |
| Molecular Weight | 508.23 |
| Formula | C18H16F3IN2O4 |
| Cas No. | 2581116-22-3 |
| Smiles | O=C(NOCCC1OCCO1)C2=CC=C(F)C(F)=C2NC3=CC=C(I)C=C3F |
Storage & Solubility Information
| Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (157.41 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy PD0325901-O-C2-dioxolane | purchase PD0325901-O-C2-dioxolane | PD0325901-O-C2-dioxolane cost | order PD0325901-O-C2-dioxolane | PD0325901-O-C2-dioxolane chemical structure | PD0325901-O-C2-dioxolane in vitro | PD0325901-O-C2-dioxolane formula | PD0325901-O-C2-dioxolane molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.